LAKE FOREST, CA--(Marketwire - Dec 21, 2012) - TRIMEDYNE, INC. ("Trimedyne") (
Urodyne and Hyperdyne are both subsidiaries Trimedyne plans to organize, subject to their obtaining $18 million and $15 million, respectively, of private financing, to conduct the above clinical trials of Trimedyne's new breakthrough lasers and disposable fiber-optic devices (See Trimedyne's Press Release of November 28, 2012).
Dr. Watson will select medical centers in Europe and the Middle East to participate, if funded, in Urodyne's and Hyperdyne's clinical trials and will train and supervise their physicians in the conduct of these clinical trials.
Dr. Watson is an internationally respected Urologist and has lectured on the use of lasers in Urology throughout Europe and the Middle East. He has authored or co-authored 56 Published Papers, been awarded 2 Scientific Prizes, has 23 Medical Appointments, prepared 3 Editorial Board Chapters and conducted 151 Lectureships.
Trimedyne manufactures proprietary Holmium lasers and patented and patent pending fiber optic laser devices to treat a variety of medical conditions in minimally invasive, procedures, many of which are performed on an outpatient basis at substantially less cost than conventional surgery. For product, press release, financial, SEC Reports and other information, please visit Trimedyne's website, http://www.trimedyne.com.
"Safe Harbor" Statement Under the Private Securities Litigation Reform Act:
Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934, including words like "believe," "expect," "may," "could" and others. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's current Form 10-K Report and subsequently filed SEC Reports. There is no assurance such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in the statements in such Reports, which Trimedyne has no obligation to update.